The move is set to bolster advancements in point-of-care medical imaging and interventions with next-generation MRI systems. Credit: Michal Jarmoluk/Pixabay.

Zydus Lifesciences‘ venture capital arm Zynext Ventures has announced a strategic investment in Promaxo, which develops low-field MRI systems.

US-based Promaxo is also engaged in the development of minimally invasive robotics.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This move is set to bolster advancements in point-of-care medical imaging and interventions with next-generation MRI systems.

Promaxo’s portable MRI system is said to be the first in the US to obtain Food and Drug Administration (FDA) 510(k) approval for prostate biopsy and treatment.

It stands out from traditional MRI technology with its open and compact design, allowing it to be placed directly in clinics or operating rooms.

It is also compatible with robotic procedures, enhancing precision in medical interventions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Promaxo is currently seeking FDA clearance for its own robot, aiming to improve the predictability and precision of prostate interventions.

Zydus Lifesciences managing director Sharvil Patel said: “This investment underscores Zydus’ commitment to supporting innovations that address unmet medical needs.

“Promaxo’s combination of accessible MRI technology and robotics for guided interventions has the potential to significantly improve patient outcomes and broaden access to vital point-of-care image-guided interventions for all.”

Promaxo is actively working to extend its applications to include female pelvic health, kidney, breast and orthopaedic conditions, broadening the scope of its innovative solutions in the healthcare sector.

Promaxo founder and CEO Dr Amit Vohra said: “We are thrilled to partner with Zynext Ventures and leverage their extensive expertise in the healthcare sector. This investment will accelerate our mission to enhance quality of care and patients’ lives through customer-centric technology. Zynext’s support helps us bring our cutting-edge solutions to a broader market.”